A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors

被引：4
|
作者：
Rosen, L. S. [1 ]
Wesolowski, R. [2 ]
Gibson, B. [3 ]
Baffa, R. [3 ]
Liao, K. H. [3 ]
Masters, J. [3 ]
Hua, S. Y. [3 ]
Deng, S. [3 ]
Shazer, R. [3 ]
Tolcher, A. W. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Med Ctr,Dept Med 9, Los Angeles, CA 90095 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Breast Canc Res Program, Columbus, OH 43210 USA
[3] Pfizer Inc, Biotechnol Clin Dev, La Jolla, CA USA
[4] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31948-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30LBA
引用
收藏
页码：S725 / S725
页数：1
相关论文
共 50 条
  • [21] Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.
    Mileshkin, L. R.
    Rosen, L. S.
    Blumenkopf, T.
    Breazna, A.
    Darang, S.
    Davison, J.
    Gallo, J.
    Goldman, J. W.
    Wang, D. D.
    Zhang, S.
    Eckhardt, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
    Taylor, Matthew H.
    Naing, Aung
    Powderly, John
    Woodard, Paul
    Chung, Luke
    Lin, Wen Hong
    Tian, Hongyu
    Siemers, Nathan
    Xiang, Hong
    Deng, Rong
    Hong, Kyu
    Valencia, Donna
    Huang, Tao
    Zhu, Ying
    Liao, X. Charlene
    Schebye, Xiao Min
    Patel, Manish R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
  • [23] Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors
    Shimizu, Toshio
    Powderly, John
    Sharma, Manish R.
    Guan, Xiaowen
    Vasilopoulos, Athanasios
    Li, Martha
    Li, Rui
    Cunningham, Alexis
    Reilly, Regina
    Morrison-Thiele, Gladys
    Freise, Kevin
    Aristide, Martha Neagu
    Camidge, D. Ross
    ANNALS OF ONCOLOGY, 2023, 34 : S1397 - S1397
  • [24] RESULTS OF A PHASE 1, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACOKINETICS OF SILTUXIMAB, AN ANTI-IL-6 ANTIBODY IN PATIENTS WITH SOLID TUMORS
    Kurzrock, R.
    Cohen, S.
    Tabernero, J.
    van Laethem, J.
    Vermeulen, J.
    Tromp, B.
    Bandekar, R.
    Puchalski, T.
    Cornfeld, M.
    Angevin, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 171 - 171
  • [25] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [26] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
    Bendell, Johanna
    Blumenschein, George
    Zinner, Ralph
    Hong, David
    Jones, Suzanne
    Infante, Jeffrey
    Burris, Howard
    Rajagopalan, Prabhu
    Kornacker, Martin
    Henderson, David
    Kelly, Andrea
    Hassan, Raffit
    CANCER RESEARCH, 2013, 73 (08)
  • [27] Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
    Infante, Jeffrey R.
    Camidge, D. Ross
    Mileshkin, Linda R.
    Chen, Eric X.
    Hicks, Rodney J.
    Rischin, Danny
    Fingert, Howard
    Pierce, Kristen J.
    Xu, Huiping
    Roberts, W. Gregory
    Shreeve, S. Martin
    Burris, Howard A.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1527 - 1533
  • [28] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
    Amita Patnaik
    Glen J. Weiss
    Drew W. Rasco
    Lisa Blaydorn
    Amy Mirabella
    Murali Beeram
    Wei Guo
    Sharon Lu
    Hadi Danaee
    Kristen McEachern
    Ellie Im
    Jasgit C. Sachdev
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
  • [29] A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
    Saif, Muhammad Wasif
    Takimoto, Chris
    Mita, Monica
    Banerji, Udai
    Lamanna, Nicole
    Castro, Januario
    O'Brien, Susan
    Stogard, Christopher
    Von Hoff, Daniel
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 445 - 455
  • [30] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Frentzas, Sophia
    Lemech, Charlotte Rose
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345